Automated Fetal Cardiac Function in Babies Affected by Heart Diseases

Automated Fetal Cardiac Function Parameters in Congenital Heart Disease

The goal of this international multicentre prospective observational cohort study with a nested case-control study is to test some automated fetal heart functional parameters in healthy babies compared to those affected by a congenital heart condition.

The main questions it aims to answer are:

• If there is a significant difference between the two populations of infants
• Whether these parameters could significantly improve the predictive value of actual cardiovascular profile score to predict hydrops Participants will be offered two automated cardiac function assessments between 27+6 and 29+6 gestational weeks and between 34+6 and 36+6 weeks of gestation. Functional parameters will be compared between the two study groups and evaluated over time.

Study Overview

• Status: Recruiting
• Conditions: Congenital Heart Defect; Cardiac Function
• Intervention / Treatment: Diagnostic test: Automated fetal cardiac function evaluation

Detailed Description

Investigation Plan

Participating patients will be offered a fetal cardiac function echocardiography between 27+6 and 29+6 weeks of gestation and another between 34+6 and 36+6 weeks.

At the stage patients will come in to carry out fetal cardiac function echocardiography they will already know whether the baby is affected by congenital heart disease since malformation screening is carried out between 18 and 20 gestational weeks and will have already been undertaken. In the remote case of detecting an undiagnosed fetal malformation during one of the research scans, patients will be reassured, and appointments arranged at Maternal and Fetal medicine (MFM) clinic for further consultation along with notification of to their own treating doctor.

Every participant will be assigned a study number following recruiting order of participation. De-identification will be undertaken at image acquisition by the doctors prior to image review by the engineers. Researchers will access an online patients' form system, collect the assigned patients' number and add the necessary outcomes information. Ultrasound images will be saved locally in the ultrasound machine by the same assigned patient's study number and uploaded to a specific Microsoft (OneDrive) folder created in Sydney. This data will be stored for a minimum of 5 years after publication, then the data record will be securely destroyed in accordance with the University of New South Wales (UNSW) Records Disposal processes.

The research ultrasound scans will be performed by a trained sonographer using either a clinical ultrasound system or a research ultrasound system that is Therapeutic Goods Administration (TGA) approved for research imaging. The machine used clinically is made by one of the common commercial manufacturers (in this case General Electric E10) and is an identical model to that used in the Department of Maternal and Fetal Medicine. The machine used for research porpoises is called Vantage 256 and it is manufactured by a private company in the United States (Verasonics). It uses the same fundamental electronic circuitry and transducer design as conventional commercial machines, and in fact uses the same transducers as the commercial machines. However, the way that the ultrasound is delivered differs. Instead of transmitting beams as used in conventional ultrasound machines, Verasonics scans the area of interest by unfocused waves, allowing high quality images with a limited number of compounded plane-waves, and reduced acquisition time.

Women will be placed in a semi-recumbent position, as standard for pregnancy ultrasounds. After routine biometry, the research fetal cardiac function ultrasound will be carried out.

Each fetal cardiac function examination will include the following parameters:

1. Fetal biometric parameters (biparietal diameter, head circumference, abdominal circumference, femur diaphysis length)
2. Standard fetal Doppler parameters (umbilical artery, medial cerebral artery, ductus venosus)
3. Fetal cardiac heart rate
4. Presence of pericardial effusion or hydrops

5. Cardiac morphometry - all measurements carried out at the end of diastole, with the exception of atrial dimensions measured in systole (at their maximum extension)

   • Heart/thorax area measurement
   • 4 heart chambers measurements (apical/basal 4-chambers view in 2D)
   • Atrial and ventricular areas (apical/basal 4-chambers view in 2D)
   • Ventricular and atrial sphericity calculation
   • Inter-ventricular septum and myocardial walls thickness measurement (transversal 4-chambers view in 2D or M-mode)

6. Cardiac contractility

   • Spatio-temporal image correlation (STIC) M-Mode stroke volume, ejection fraction and shortening fraction
   • Automated STIC Mitral Annular Plane Systolic Excursion (MAPSE), Tricuspid Annular Plane Systolic Excursion (TAPSE), Septal Annular Plane Systolic Excursion (SAPSE)
   • Automated Pulsed Wave Doppler (PWD) Left and Right modified myocardial performance index (Mod-MPI)

7. Atrioventricular valves' function evaluation

   • Cine-loop evaluation of correct opening and closing
   • Anterograde Colour Doppler without regurgitation
   • Pulsed Doppler evaluation of flow velocity (monophasic or biphasic)
   • Left and right E/A ratio calculation
   • If any regurgitation: peak velocity and duration quantified

8. Aorta outflow evaluation

   • Aorta artery measurement (at the level of valvular ring in systole)
   • Aortic flow evaluation (Colour Doppler evaluation of systolic peak velocity)

9. Pulmonary outflow evaluation

   • Pulmonary artery measurement (at the level of valvular ring in systole)
   • Pulmonary flow evaluation (Colour Doppler evaluation of systolic peak velocity)

10. V-sign evaluation

    • Confirmation of anterograde flow in the entire length of the arteries
    • Pulsatility index of aortic isthmus and ductus arteriosus

All fetal morphometric and functional cardiac parameters will be normalised to Z-score by gestational age where possible. Fetal cardiac volumes and 2D images with inadequate quality due to fetal movements, presence of acoustic shadows of fetal ribs or spine, and maternal breathing will be excluded. If hydrops develops, cardiovascular profile score will be added to the routine cardiac function exploration.

The study population will be followed up until delivery and discharge of both mother and neonate. Patients' information will be collected anonymously. Each patient's history will be evaluated and information about previous pregnancies (maternal or fetal diseases during pregnancy) and outcomes (type of delivery, maternal and neonatal conditions at birth, long-term outcome of the pregnancy) will be collected. Furthermore, investigators plan to collect information about the current pregnancy (maternal and fetal observations during pregnancy) and outcomes (type of delivery, maternal and neonatal conditions at birth and up to hospital discharge of both).

Study Procedure Risks

There is no increased risk related to participating in this study. The study uses conventional ultrasound machinery as used in routine fetal evaluation, with no alteration in power output (as defined by Thermal Index or Mechanical Index). The Verasonics research ultrasound system is also comparable to conventional ultrasounds in terms of risks.

Approximately 20-30 minutes scan duration is anticipated for acquisition of the necessary research data which is in keeping with standard ultrasound examinations, and the As Low As Reasonably Achievable (ALARA) principle conventionally applied in fetal imaging.

Sample Size Calculation

The primary outcome of the study is the difference in the mean of automated fetal functional cardiac parameters between CHD cases and controls. This will be analysed using a two-sample t-test.

To estimate the sample size, the most commonly applied fetal functional parameter was used, specifically the left ventricle MPI (LV-MPI) as a proxy of all the automated fetal cardiac parameters.

Due to the rarity of congenital heart disease, the sample size calculation was performed based on recruiting two controls for each case. Pooled across cases with isolated pulmonary valve stenosis (n = 16) and controls (n = 48), a previous work observed a standard deviation of 0.098 in LV-MPI measurements. Using this observed pooled Standard Deviation (SD), a total sample of 381 pregnancies (127 CHD + 254 controls) with completed measurements is required to achieve at least 80% power to detect a difference of 0.03 in mean LV-MPI, with a two-sided type I error rate of 5%.

Investigators acknowledge that some pilot data may be required to evaluate the limited number of pathological cases and therefore some approximations are necessary e.g. for standard deviation within the population. For this reason, investigators have aimed to recruit a larger number of participants (approximately 30%), 165 CHD and 330 Controls, allowing also for some patient exclusions due to patient drop out, difficulties in scanning due to fetal movements etc, and incomplete data sets.

The aim would be to recruit sufficient cases to be able to estimate if there is significant difference in terms of fetal cardiac function parameters between affected and not affected fetuses to inform further research.

Data Analysis Plan

Raw (radio-frequency) ultrasound data generated using the Verasonics will allow the researchers to analyse the signal/image processing that takes place prior to display, enabling refinement of this imaging technique.

Image analysis will be carried out first manually through optical evaluation and then through the use of mathematical algorithms which will recognise and analyse only high-quality images. This could be a limitation because automatically only high-quality images will be included (which is not representative of real clinical work) but also guarantees that parameters are collected only from almost perfect research material (showing true differences if they exist).

Ultrasound images will be analysed and cardiac function parameters interpreted by South Eastern Sydney Local Health District (SESLHD)/UNSW researchers based at the Royal Hospital for Women (RHW), Randwick. Images will be analysed by a team of fetal medicine doctors at Royal Hospital for Women and UNSW engineers to assure that algorithms are correctly applied to calculate fetal cardiac function parameters.

Comparisons of interest between cases and controls in baseline characteristics will be performed using two-sample t-tests, Wilcoxon rank-sum tests or Pearson Chi-squared tests, as appropriate.

Secondary outcomes comparing cases and controls at a single time point will be analysed in a similar way to the primary outcome, subject to checks of assumptions. Analyses of changes in fetal function parameters over time (i.e. between the 27+6-29+6 and 34+6-36+6 week scans), and the comparison of these changes between cases and controls will employ generalised linear mixed models, as appropriate for the parameter.

Logistic regression will be used to estimate the association between fetal cardiac parameters and the incidence of hydrops. Receiver-operating-characteristics-curve analysis will be carried out to assess functional cardiac parameters compared to the routinely used cardiovascular profile score to predict cardiac failure in fetuses with congenital heart disease.

Statistical analysis will be performed using SPSS version 22.0 (SPSS Inc., Chicago, Illinois (IL), USA).

For those cases without complete data acquisition (i.e. intending but not undertaking a second scan), analysis will take place for only the isolated value and not for any temporal change. Their single gestational data set of ultrasound measurements will still be included in analysis but excluded from any analysis of sequential change.

Data Safety and Monitoring Board

To assure high quality data collection, images will be collected at each participating centre by experienced fetal medicine doctors who have practiced fetal medicine for over 10 years. Each image will be stored securely. Data will be anonymised and monitored by researchers at SESLHD/UNSW. Researchers at UNSW will also review and complete data collection in case of missing data.

Our team from RHW will supervise and guarantee the quality of the data. Each participating centre will have a site researcher, a fetal cardiologist who will discuss and sign consent form, collect ultrasound images and relevant patients' data. The data collected will be uploaded and securely stored onto the UNSW platform.

Once ethical approval for each overseas center will be granted, UNSW team will download data from all centers, merge the information in a unique database and analyze them with the help of a statistician. UNSW team will be responsible for images analysis and data analysis. All the participants will then collaborate in drafting manuscripts for publication.

Outcome data will be accessed only by authorised researchers using an encrypted code for data protection. Final drafts for publication will be reviewed by all the authors from each research site.

Dissemination of results and publication policy

Results of the study will be published in peer-reviewed scientific journals, presentations at conferences or other professional forums. In any publication, patient privacy will be protected and presented in a de-identified manner.

• Study Type: Observational
• Enrollment (Estimated): 495

Contacts and Locations

• Study Contact: Name: Anna Erenbourg, MD; Phone Number: +61423879866; Email: a.erenbourg@unsw.edu.au
• Study Contact Backup: Name: Alec W Welsh, MD PhD; Email: alec.welsh@unsw.edu.au

Study Locations

• Australia
  • New South Wales
    • Sydney, New South Wales, Australia
      • Recruiting
      • Royal Hospital for Women
      • Contact: Alec Welsh; Email: alec.welsh@unsw.edu.au
      • Contact: Anna Erenbourg; Email: a.erenbourg@unsw.edu.au
• Israel
  • Tel Aviv, Israel
    • Not yet recruiting
    • Sheba Medical Center
    • Contact: Hagai Avnet; Email: hagai.Avnet@sheba.health.gov.il
• Italy
  • L'Aquila, Italy
    • Not yet recruiting
    • San Salvatore Hospital L'Aquila
    • Contact: Ilaria Fantasia; Email: ilariafantasia@gmail.com
    • Contact: Sara tabacco; Email: saratabacco87@gmail.com
  • Milan, Italy
    • Not yet recruiting
    • Vittore Buzzi Children's Hospital
    • Contact: Stefano Faiola; Email: stefanofaiola@hotmail.com
    • Contact: Chiara Coco; Email: chiaracoco401@gmail.com
  • Trieste, Italy
    • Not yet recruiting
    • Institute for Maternal and Child Health IRCCS Burlo Garofolo
    • Contact: Tamara Stampalija; Email: tamara.stampalija@burlo.trieste.it
    • Contact: Sofia Bussolaro; Email: sofia.bussolaro91@gmail.com
• Mayotte
  • Mamoudzou, Mayotte
    • Not yet recruiting
    • Centre Hospitalier de Mayotte
    • Contact: Vera Cecotti; Email: veradott@gmail.com
• Poland
  • Kraków, Poland
    • Not yet recruiting
    • Medical Center Ujastek
    • Contact: Beata Radzymińska-Chruściel; Email: bearad63@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Pregnant women will be recruited from each participating centre during their second or third trimester morphology scan.

The Control Group will be mostly recruited at the time of the second trimester morphology scan; the CHD Group during a second/third trimester anomaly scan with collaboration and referral from the hospital fetal cardiologist.

Healthy patients will be approached in the waiting room after their second trimester ultrasound scan, offered to participate and given a copy of a patient information sheet and consent form.

CHD patients will be approached and offered to participate after consultation with perinatal cardiologists. A week after the first contact, we will phone patients to verify their intention to take part and to organize the fetal cardiac function follow up.

Description

Inclusion Criteria:

• Inclusion criteria for the CHD Group are as follows: singleton pregnancies; gestational age between 19+6 and 36+6 weeks gestation, determined by the last menstrual period and confirmed by first trimester ultrasound; isolated congenital cardiac anomaly diagnosed.
• Inclusion criteria for the Control Group are as follows: singleton pregnancies; gestational age between 19+6 and 27+6 weeks gestation, determined by the last menstrual period and confirmed by first trimester ultrasound; no congenital cardiac anomaly diagnosed

Exclusion Criteria common to the 2 groups (Cases and Controls):

• Fetuses whose mothers have comorbidities that have been proven to potentially affect cardiac function including:

  • intrahepatic cholestasis
  • pre-gestational and gestational diabetes
  • preeclampsia
  • growth restricted fetuses defined as estimated fetal weight or abdominal circumference <3rd percentile for GA
• Fetuses with other structural extracardiac anomalies at ultrasound examination
• Fetuses affected by any diagnosed genetic abnormalities

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cases; Singleton pregnancies affected by congenital heart disease	Diagnostic test: Automated fetal cardiac function evaluation; Evaluation of ultrasound parameters by automated algorithms. Ultrasound assessed parameters are: Pulsed wave Doppler Modified Left and Right Myocardial performance indices; Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion
Controls; Singleton healthy pregnancies	Diagnostic test: Automated fetal cardiac function evaluation; Evaluation of ultrasound parameters by automated algorithms. Ultrasound assessed parameters are: Pulsed wave Doppler Modified Left and Right Myocardial performance indices; Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Automated PWD-MPI comparing fetuses affected by congenital heart disease (CHD) to reference values across the fetal healthy population.	Measure the difference in the mean absolute numerical value for PWD-MPI (expressed to 2 decimal places) between fetuses with CHD overall compared to healthy fetuses and then by subgroups of different CHDs.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks
Automated PWD-MPI comparing fetuses affected by congenital heart disease (CHD) to reference values across the fetal healthy population.	Measure the difference in the mean absolute numerical value for PWD-MPI (expressed to 2 decimal places) between fetuses with CHD overall compared to healthy fetuses and then by subgroups of different CHDs.	Measurements undertaken within the range 34+6 - 36+6 gestational weeks
Automated PWD-MPI comparing fetuses affected by congenital heart disease (CHD) to reference values across the fetal healthy population.	Difference in variation of the mean absolute value for PWD-MPI over time between fetuses with CHD overall compared to healthy fetuses and then by subgroups of different CHDs.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks and within the range 34+6 - 36+6 gestational weeks
Automated STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion comparing fetuses affected by congenital heart disease to reference values across the fetal healthy population.	Difference in absolute values for each of STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion between fetuses with CHD overall compared to healthy fetuses and then by subgroups of different CHDs.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks
Automated STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion comparing fetuses affected by congenital heart disease to reference values across the fetal healthy population.	Difference in absolute values for each of STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion between fetuses with CHD overall compared to healthy fetuses and then by subgroups of different CHDs.	Measurements undertaken within the range 34+6 - 36+6 gestational weeks
Automated STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion comparing fetuses affected by congenital heart disease (CHD) to reference values across the fetal healthy population.	Difference in variation of absolute values for each of STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion between fetuses with CHD overall compared to healthy fetuses and then by subgroups of different CHDs.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks and within the range 34+6 - 36+6 gestational weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Predictive value of Modified Cardiovascular Profile Score in hydrops (Adding Automated PWD-MPI to the classical cardiovascular profile score).	Difference in predictive values between Modified and Classical Cardiovascular Profile Score. Minimum score value is 0, Maximum score value is 12. Higher score means a better outcome.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks.
Predictive value of Modified Cardiovascular Profile Score in hydrops (Adding Automated PWD-MPI to the classical cardiovascular profile score).	Difference in predictive values between Modified and Classical Cardiovascular Profile Score. Minimum score value is 0, Maximum score value is 12. Higher score means a better outcome.	Measurements undertaken within the range 34+6 - 36+6 gestational weeks.
Predictive value of Modified Cardiovascular Profile Score in hydrops (Adding Automated STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion to the classical cardiovascular profile score).	Difference in predictive values between Modified and Classical Cardiovascular Profile Score. Minimum score value is 0, Maximum score value is 12. Higher score means a better outcome.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks.
Predictive value of Modified Cardiovascular Profile Score in hydrops (Adding Automated STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion to the classical cardiovascular profile score).	Difference in predictive values between Modified and Classical Cardiovascular Profile Score. Minimum score value is 0, Maximum score value is 12. Higher score means a better outcome.	Measurements undertaken within the range 34+6 - 36+6 gestational weeks.
Predictive value of Modified Cardiovascular Profile Score in hydrops (Adding Automated PW-MPI and STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion to the classical cardiovascular profile score).	Difference in predictive values between Modified and Classical Cardiovascular Profile Score. Minimum score value is 0, Maximum score value is 14. Higher score means a better outcome.	Measurements undertaken within the range 27+6 - 29+6 gestational weeks.
Predictive value of Modified Cardiovascular Profile Score in hydrops (Adding Automated PW-MPI and STIC Tricuspid, Mitral and Septal Annular Plane Systolic Excursion to the classical cardiovascular profile score).	Difference in predictive values between Modified and Classical Cardiovascular Profile Score. Minimum score value is 0, Maximum score value is 14. Higher score means a better outcome.	Measurements undertaken within the range 34+6 - 36+6 gestational weeks.

Collaborators and Investigators

• Sponsor: Anna Erenbourg
• Collaborators: Sheba Medical Center; San Salvatore Hospital of L'Aquila; Vittore Buzzi Children's Hospital; Centre Hospitalier de Mayotte; Institute for Maternal and Child Health IRCCS Burlo Garofolo; Clinic of Fetal Echocardiography, Medical Centre UJASTEK
• Investigators: Principal Investigator: Anna Erenbourg, MD, The University of New South Wales; Study Director: Alec W Welsh, MD PhD, The University of New South Wales

Publications and helpful links

General Publications

• Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000 Mar 1;35(3):569-82. doi: 10.1016/s0735-1097(99)00630-0.
• Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC Sr, Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J; American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014 May 27;129(21):2183-242. doi: 10.1161/01.cir.0000437597.44550.5d. Epub 2014 Apr 24. Erratum In: Circulation. 2014 May 27;129(21):e512.
• Wu W, He J, Shao X. Incidence and mortality trend of congenital heart disease at the global, regional, and national level, 1990-2017. Medicine (Baltimore). 2020 Jun 5;99(23):e20593. doi: 10.1097/MD.0000000000020593.
• Crispi F, Sepulveda-Martinez A, Crovetto F, Gomez O, Bijnens B, Gratacos E. Main Patterns of Fetal Cardiac Remodeling. Fetal Diagn Ther. 2020;47(5):337-344. doi: 10.1159/000506047. Epub 2020 Mar 26.
• Walter C, Soveral I, Bartrons J, Escobar MC, Carretero JM, Quirado L, Gomez O, Sanchez-de-Toledo J. Comprehensive Functional Echocardiographic Assessment of Transposition of the Great Arteries: From Fetus to Newborn. Pediatr Cardiol. 2020 Apr;41(4):687-694. doi: 10.1007/s00246-019-02279-w. Epub 2020 Jan 10.
• Guirado L, Crispi F, Masoller N, Bennasar M, Marimon E, Carretero J, Gratacos E, Martinez JM, Friedberg MK, Gomez O. Biventricular impact of mild to moderate fetal pulmonary valve stenosis. Ultrasound Obstet Gynecol. 2018 Mar;51(3):349-356. doi: 10.1002/uog.17456.
• Inamura N, Taketazu M, Smallhorn JF, Hornberger LK. Left ventricular myocardial performance in the fetus with severe tricuspid valve disease and tricuspid insufficiency. Am J Perinatol. 2005 Feb;22(2):91-7. doi: 10.1055/s-2005-837739.
• Lasa JJ, Tian ZY, Guo R, Rychik J. Perinatal course of Ebstein's anomaly and tricuspid valve dysplasia in the fetus. Prenat Diagn. 2012 Mar;32(3):245-51. doi: 10.1002/pd.2939.
• Wohlmuth C, Wertaschnigg D, Wieser I, Arzt W, Tulzer G. Tissue Doppler imaging in fetuses with aortic stenosis and evolving hypoplastic left heart syndrome before and after fetal aortic valvuloplasty. Ultrasound Obstet Gynecol. 2016 May;47(5):608-15. doi: 10.1002/uog.14885. Epub 2016 Apr 17.
• Chen J, Xie L, Dai L, Yu L, Liu L, Zhou Y, Wu G, Qin F, Liu H. Right Heart Function of Fetuses and Infants with Large Ventricular Septal Defect: A Longitudinal Case-Control Study. Pediatr Cardiol. 2016 Dec;37(8):1488-1497. doi: 10.1007/s00246-016-1462-z. Epub 2016 Aug 25.
• Natarajan S, Szwast A, Tian Z, McCann M, Soffer D, Rychik J. Right ventricular mechanics in the fetus with hypoplastic left heart syndrome. J Am Soc Echocardiogr. 2013 May;26(5):515-20. doi: 10.1016/j.echo.2013.02.001. Epub 2013 Mar 6.
• Nawaytou HM, Peyvandi S, Brook MM, Silverman N, Moon-Grady AJ. Right Ventricular Systolic-to-Diastolic Time Index: Hypoplastic Left Heart Fetuses Differ Significantly from Normal Fetuses. J Am Soc Echocardiogr. 2016 Feb;29(2):143-9. doi: 10.1016/j.echo.2015.08.014. Epub 2015 Sep 26.
• Chen Y, Lv G, Li B, Wang Z. Cerebral vascular resistance and left ventricular myocardial performance in fetuses with Ebstein's anomaly. Am J Perinatol. 2009 Apr;26(4):253-8. doi: 10.1055/s-0028-1103152. Epub 2008 Nov 20.
• Khandoker AH, Al-Angari HM, Marzbanrad F, Kimura Y. Investigating fetal myocardial function in heart anomalies by Doppler myocardial performance indices. Annu Int Conf IEEE Eng Med Biol Soc. 2017 Jul;2017:2197-2200. doi: 10.1109/EMBC.2017.8037290.
• Axt-Fliedner R, Graupner O, Kawecki A, Degenhardt J, Herrmann J, Tenzer A, Doelle A, Willruth A, Steinhard J, Gembruch U, Bahlmann F, Enzensberger C; Fetal Cardiac Imaging Research Group, Germany. Evaluation of right ventricular function in fetuses with hypoplastic left heart syndrome using tissue Doppler techniques. Ultrasound Obstet Gynecol. 2015 Jun;45(6):670-7. doi: 10.1002/uog.14736. Epub 2015 May 11.
• Graupner O, Enzensberger C, Wieg L, Willruth A, Steinhard J, Gembruch U, Doelle A, Bahlmann F, Kawecki A, Degenhardt J, Wolter A, Herrmann J, Axt-Fliedner R; Fetal Cardiac Imaging Research Group Germany. Evaluation of right ventricular function in fetal hypoplastic left heart syndrome by color tissue Doppler imaging. Ultrasound Obstet Gynecol. 2016 Jun;47(6):732-8. doi: 10.1002/uog.14940.
• Pedra SR, Hornberger LK, Leal SM, Taylor GP, Smallhorn JF. Cardiac function assessment in patients with family history of nonhypertrophic cardiomyopathy: a prenatal and postnatal study. Pediatr Cardiol. 2005 Sep-Oct;26(5):543-52. doi: 10.1007/s00246-004-0688-3.
• Clur SB, Vink AS, Etheridge SP, Robles de Medina PG, Rydberg A, Ackerman MJ, Wilde AA, Blom NA, Benson DW, Herberg U, Donofrio MT, Cuneo BF. Left Ventricular Isovolumetric Relaxation Time Is Prolonged in Fetal Long-QT Syndrome. Circ Arrhythm Electrophysiol. 2018 Apr;11(4):e005797. doi: 10.1161/CIRCEP.117.005797.
• Yozgat Y, Kilic A, Ozdemir R, Karadeniz C, Kucuk M, Karaarslan U, Mese T, Unal N. Modified myocardial performance index is not affected in fetuses with an isolated echogenic focus in the left ventricle. J Matern Fetal Neonatal Med. 2015 Feb;28(3):333-7. doi: 10.3109/14767058.2014.916679. Epub 2014 May 22.
• Acharya G, Pavlovic M, Ewing L, Nollmann D, Leshko J, Huhta JC. Comparison between pulsed-wave Doppler- and tissue Doppler-derived Tei indices in fetuses with and without congenital heart disease. Ultrasound Obstet Gynecol. 2008 Apr;31(4):406-11. doi: 10.1002/uog.5292.
• Patey O, Carvalho JS, Thilaganathan B. Urgent neonatal balloon atrial septostomy in simple transposition of the great arteries: predictive value of fetal cardiac parameters. Ultrasound Obstet Gynecol. 2021 May;57(5):756-768. doi: 10.1002/uog.22164.
• Crispi F, Valenzuela-Alcaraz B, Cruz-Lemini M, Gratacos E. Ultrasound assessment of fetal cardiac function. Australas J Ultrasound Med. 2013 Nov;16(4):158-167. doi: 10.1002/j.2205-0140.2013.tb00242.x. Epub 2015 Dec 31.
• Acharya G, Archer N, Huhta JC. Functional assessment of the evolution of congenital heart disease in utero. Curr Opin Pediatr. 2007 Oct;19(5):533-7. doi: 10.1097/MOP.0b013e3282efd2a2.
• Maheshwari P, Henry A, Welsh AW. The Fetal Modified Myocardial Performance Index: Is Automation the Future? Biomed Res Int. 2015;2015:215910. doi: 10.1155/2015/215910. Epub 2015 Jun 22.
• Herling L, Johnson J, Ferm-Widlund K, Zamprakou A, Westgren M, Acharya G. Automated quantitative evaluation of fetal atrioventricular annular plane systolic excursion. Ultrasound Obstet Gynecol. 2021 Dec;58(6):853-863. doi: 10.1002/uog.23703.
• Garcia-Canadilla P, Sanchez-Martinez S, Crispi F, Bijnens B. Machine Learning in Fetal Cardiology: What to Expect. Fetal Diagn Ther. 2020;47(5):363-372. doi: 10.1159/000505021. Epub 2020 Jan 7.
• Liu Y, Chen S, Zuhlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019 Apr 1;48(2):455-463. doi: 10.1093/ije/dyz009.
• Tan CMJ, Lewandowski AJ. The Transitional Heart: From Early Embryonic and Fetal Development to Neonatal Life. Fetal Diagn Ther. 2020;47(5):373-386. doi: 10.1159/000501906. Epub 2019 Sep 18.
• Peixoto AB, Bravo-Valenzuela NJ, Rocha LA, Araujo Junior E. Spectral Doppler, tissue Doppler, and speckle-tracking echocardiography for the evaluation of fetal cardiac function: an update. Radiol Bras. 2021 Mar-Apr;54(2):99-106. doi: 10.1590/0100-3984.2020.0052.
• Wieczorek A, Hernandez-Robles J, Ewing L, Leshko J, Luther S, Huhta J. Prediction of outcome of fetal congenital heart disease using a cardiovascular profile score. Ultrasound Obstet Gynecol. 2008 Mar;31(3):284-8. doi: 10.1002/uog.5177.
• Huhta JC. Diagnosis and treatment of foetal heart failure: foetal echocardiography and foetal hydrops. Cardiol Young. 2015 Aug;25 Suppl 2:100-6. doi: 10.1017/S104795111500089X.

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2023
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): February 1, 2028

Study Registration Dates

• First Submitted: December 18, 2022
• First Submitted That Met QC Criteria: January 15, 2023
• First Posted (Actual): January 26, 2023

Study Record Updates

• Last Update Posted (Actual): November 30, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Congenital Heart Diseases; Fetal Cardiac Function
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Congenital Abnormalities; Cardiovascular Abnormalities; Heart Diseases; Heart Defects, Congenital
• Other Study ID Numbers: 2022/ETH00943

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All Individual Participant Data (IPD) that underlie results will be shared with other researchers in a publication.
• IPD Sharing Time Frame: Data will become available from 6 months after publication.
• IPD Sharing Access Criteria: Data will be accessible online on request by researchers. Requests will be reviewed and evaluated by the Principal Investigator. Data will be available for meta-analyses involving the collection, checking, and re-analysis of the original data for each participant in each study.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No